Portfolio news Archives - Page 9 of 13

Accessing TCR Discovery Capabilities with Alloy Therapeutics

In particular, TCR-based therapeutics hold great promise to improve immunotherapies, as T cells are key players in adaptive immune response leading to curative effects in…

Arianna30.06.2022

Portfolio news Uncategorized

BaseLaunch Summer Get-Toghether 2022

We are very pleased to have had so many experts, partners, and friends joining our Summer Get-together this year! Check below some of our memories…

Arianna30.06.2022

Portfolio news

Lonza announces collaboration with BaseLaunch

Lonza works to enable a healthier world by supporting customers to deliver new and innovative medicines that help treat a wide range of diseases. Their…

Arianna23.06.2022

Anaveon_-startups_Switzerland-credit-Jasmin-Rei

Portfolio news

Anaveon announces starting efficacy trials with ANV419, their powerful and selective IL-2 agonist.

One of our portfolio companies, Anaveon AG, announces FDA Safe to proceed letter for Investigational New Drug (IND) Application for its no-alpha IL-2 agonist, ANV419…

Arianna10.06.2022

Portfolio news

Onena Medicines joins BaseLaunch Portfolio

We are excited to welcome Onena Medicines as our newest portfolio company! Onena Medicines is a Swiss-Spanish biotech company emerging from the Chan Zuckerberg Biohub…

Arianna11.05.2022

Portfolio news

Engimmune Therapeutics raises $16.7M in seed financing co-led by Pureos Bioventures and Novo Holdings

Engimmune is a Swiss biotech company developing novel T-cell receptor (TCR)-based therapeutics, founded in August 2021 by Dr. Rodrigo Vazquez-Lombardi, Prof Sai Reddy and Dr…

Arianna03.05.2022

Portfolio news

Cimeio Therapeutics raises a 50M USD series A financing from Versant Ventures

Cimeio therapeutics is a spin-off from the University of Basel. The scientific basis was born out of years of cutting-edge research by Professor Lukas Jeker–co-founder…

Arianna13.04.2022

Portfolio news

BaseLaunch – onwards and upwards

2022 started off on some good notes for BaseLaunch, with two new companies (one still in stealth) joining our portfolio and another one announcing the…

Arianna28.02.2022

Portfolio news

Aukera Therapeutics joins BaseLaunch Portfolio

We are excited to welcome Aukera Therapeutics as our newest portfolio company! Basel, Switzerland., 15 February 2022 — Aukera Therapeutics is a spin-off from the Biozentrum…

Arianna15.02.2022

Portfolio news

Stromal Therapeutics joins BaseLaunch Portfolio

We are excited to welcome Stromal Therapeutics as our newest portfolio company! Basel, Switzerland., 28 January 2022 — Stromal Therapeutics is emerging from one of…

Arianna28.01.2022

Portfolio news

Accessing TCR Discovery Capabilities with Alloy Therapeutics

BaseLaunch Summer Get-Toghether 2022

Lonza announces collaboration with BaseLaunch

Anaveon announces starting efficacy trials with ANV419, their powerful and selective IL-2 agonist.

Onena Medicines joins BaseLaunch Portfolio

Engimmune Therapeutics raises $16.7M in seed financing co-led by Pureos Bioventures and Novo Holdings

Cimeio Therapeutics raises a 50M USD series A financing from Versant Ventures

BaseLaunch – onwards and upwards

Aukera Therapeutics joins BaseLaunch Portfolio

Stromal Therapeutics joins BaseLaunch Portfolio

Useful links

Contact us

Sign up for our newsletter and event invitations

Follow us